TRAP
MCID: TRD008
MIFTS: 33

Triiodothyronine Receptor Auxiliary Protein (TRAP)

Aliases & Classifications for Triiodothyronine Receptor Auxiliary Protein

MalaCards integrated aliases for Triiodothyronine Receptor Auxiliary Protein:

Name: Triiodothyronine Receptor Auxiliary Protein 57
Trap 57

External Ids:

OMIM® 57 190445

Summaries for Triiodothyronine Receptor Auxiliary Protein

MalaCards based summary : Triiodothyronine Receptor Auxiliary Protein, also known as trap, is related to spondyloenchondrodysplasia with immune dysregulation and neural tube defects. An important gene associated with Triiodothyronine Receptor Auxiliary Protein is TRAP (Triiodothyronine Receptor Auxiliary Protein). The drugs Heparin and Tinzaparin have been mentioned in the context of this disorder. Affiliated tissues include bone, neutrophil and endothelial.

More information from OMIM: 190445

Related Diseases for Triiodothyronine Receptor Auxiliary Protein

Diseases related to Triiodothyronine Receptor Auxiliary Protein via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 784)
# Related Disease Score Top Affiliating Genes
1 spondyloenchondrodysplasia with immune dysregulation 11.1
2 neural tube defects 11.0
3 hidradenitis suppurativa 10.9
4 immune system disease 10.9
5 malaria 10.4
6 bone resorption disease 10.2
7 vaccinia 10.2
8 vasculitis 10.2
9 macular degeneration, age-related, 1 10.2
10 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
11 hair whorl 10.2
12 west nile virus 10.2
13 lupus erythematosus 10.2
14 rapidly involuting congenital hemangioma 10.2
15 lung cancer 10.1
16 microvascular complications of diabetes 5 10.1
17 chikungunya 10.1
18 ischemia 10.1
19 encephalitis 10.1
20 rabies 10.1
21 chronic granulomatous disease 10.1
22 anca-associated vasculitis 10.1
23 cytokine deficiency 10.1
24 systemic lupus erythematosus 10.1
25 volvulus of midgut 10.1
26 proteinuria, chronic benign 10.1
27 middle east respiratory syndrome 10.1
28 hairy cell leukemia 10.1
29 acute pancreatitis 10.1
30 macular retinal edema 10.1
31 pancreatitis 10.1
32 congestive heart failure 10.1
33 polyhydramnios 10.1
34 lung disease 10.1
35 yellow fever 10.1
36 cystic fibrosis 10.1
37 helix syndrome 10.1
38 leukemia 10.1
39 periodontitis 10.1
40 peritonitis 10.1
41 arthritis 10.1
42 47,xyy 10.1
43 haemophilus influenzae 10.1
44 meester-loeys syndrome 10.0
45 kuhnt-junius degeneration 10.0
46 atrial standstill 1 10.0
47 osteogenic sarcoma 10.0
48 yemenite deaf-blind hypopigmentation syndrome 10.0
49 thrombosis 10.0
50 onchocerciasis 10.0

Graphical network of the top 20 diseases related to Triiodothyronine Receptor Auxiliary Protein:



Diseases related to Triiodothyronine Receptor Auxiliary Protein

Symptoms & Phenotypes for Triiodothyronine Receptor Auxiliary Protein

Clinical features from OMIM®:

190445 (Updated 20-May-2021)

Drugs & Therapeutics for Triiodothyronine Receptor Auxiliary Protein

Drugs for Triiodothyronine Receptor Auxiliary Protein (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
2
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
3
Dalteparin Approved Phase 4 9005-49-6
4 Certoparin Approved, Investigational Phase 4
5
Verteporfin Approved, Investigational Phase 4 129497-78-5
6
Vorapaxar Approved Phase 4 618385-01-6
7
Thrombin Approved, Investigational Phase 4
8
Rilonacept Approved, Investigational Phase 4 501081-76-1 104924
9
Ranibizumab Approved Phase 4 347396-82-1 459903
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11 Fibrinolytic Agents Phase 4
12 calcium heparin Phase 4
13 Heparin, Low-Molecular-Weight Phase 4
14
Terephthalic acid Phase 4 100-21-0 7489
15 Mitogens Phase 4
16 Endothelial Growth Factors Phase 4
17 Anti-Inflammatory Agents Phase 4
18 Vaccines Phase 4
19 Immunologic Factors Phase 4
20 Pharmaceutical Solutions Phase 4
21 Anesthetics Phase 4
22
tannic acid Approved Phase 3 1401-55-4
23
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
24
Colchicine Approved Phase 3 64-86-8 6167 2833
25 Calamus Phase 3
26 Dialysis Solutions Phase 3
27 Protamines Phase 3
28 Photosensitizing Agents Phase 3
29 Angiogenesis Inhibitors Phase 3
30 Immunoglobulins Phase 3
31 Immunoglobulins, Intravenous Phase 3
32 Antibodies Phase 3
33
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
34
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
35
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
36
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
37
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
38
Trastuzumab Approved, Investigational Phase 1, Phase 2 180288-69-1 9903
39
Pertuzumab Approved Phase 1, Phase 2 380610-27-5, 145040-37-5 2540
40
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
41
Olaparib Approved Phase 2 763113-22-0 23725625
42
Durvalumab Approved, Investigational Phase 2 1428935-60-7
43
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
44
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
45
Atezolizumab Approved, Investigational Phase 1, Phase 2 1380723-44-3
46
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
47
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
48
Clemastine Approved, Investigational Phase 1, Phase 2 15686-51-8 26987
49
Pioglitazone Approved, Investigational Phase 1, Phase 2 111025-46-8 4829
50
Dantrolene Approved, Investigational Phase 1, Phase 2 7261-97-4 2952 6914273

Interventional clinical trials:

(show top 50) (show all 196)
# Name Status NCT ID Phase Drugs
1 Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial Unknown status NCT00196417 Phase 4 Standard heparin (UFH) versus certoparin (LMWH)
2 MGuard vs bAre-metal Stents Plus Manual Thrombectomy in Real World STEMI Patients: a Prospective Multicenter Randomized Trial Unknown status NCT01124942 Phase 4
3 Reassessment Study of The Effect of N-Acetylcystein on Quality of Life and Air Trapping During Rest and After Exercise Unknown status NCT00476736 Phase 4 Effect on small airways (N-Acetylcystein)
4 Vorapaxar in the Human Endotoxemia Model A Randomized, Double-Blind, Crossover Study Completed NCT02875028 Phase 4 Vorapaxar;Placebo
5 Efficacy of Intravitreal Aflibercept Monotherapy for Submacular Hemorrhage Secondary to Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial Completed NCT03169660 Phase 4 Vascular endothelial growth factor trap-eye
6 An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration Completed NCT01722045 Phase 4 Intravitreal Aflibercept Injection (IAI)
7 Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD) Completed NCT01663103 Phase 4 Rilonacept;Placebo
8 Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab Completed NCT02309281 Phase 4 aflibercept 2mg
9 Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy Completed NCT02072408 Phase 4 aflibercept
10 An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed NCT01950741 Phase 4 aflibercept
11 Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy Recruiting NCT02621645 Phase 4
12 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples Recruiting NCT01824537 Phase 4
13 Estimation of MMP-8 Levels in GCF and Serum and Its Correlation With Wound Healing and Clinical Outcomes After Coronally Advanced Flap and Subepithelial Connective Tissue Graft for Root Coverage in Recession Defects: A CLINICO-BIOCHEMICAL STUDY Suspended NCT02863744 Phase 4
14 A Randomized Controlled Trial of Integrated Traditional Chinese and Western Medicine in the Treatment of Severe Community Acquired Pneumonia Unknown status NCT03185923 Phase 3 TCM plus conventional drug;TCM placebo plus conventional drug
15 Influence of Preoperative Hemodialysis or Intraoperative Modified Ultrafiltration on Postoperative Outcome for Patients With Severe Renal Dysfunction Undergoing Open Heart Surgery: Randomized, Controlled, Multicenter Clinical Trial Unknown status NCT00720967 Phase 3
16 A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap-Eye in Subjects With Diabetic Macular Edema Completed NCT01331681 Phase 3
17 A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema Completed NCT01783886 Phase 3
18 A Randomized, Double-masked, Photodynamic Therapy-controlled Phase-3 Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Chinese Subjects With Neovascular Age-Related Macular Degeneration Completed NCT01482910 Phase 3 Visudyne
19 An Open-label Phase III Study Evaluating the Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap-Eye in Japanese Subjects With Diabetic Macular Edema Completed NCT01512966 Phase 3
20 A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection [IAI]) in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT01521559 Phase 3 Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
21 A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD) Completed NCT00637377 Phase 3 Ranibizumab
22 An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration Completed NCT00964795 Phase 3 Intravitreal Aflibercept Injection 2mg
23 A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia Completed NCT01249664 Phase 3
24 A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-Related Macular Degeneration Completed NCT00509795 Phase 3
25 A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema Completed NCT01363440 Phase 3 Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
26 A Randomized, Double Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion Completed NCT00943072 Phase 3 Sham
27 A Randomized, Double-masked, Sham-controlled Phase 3 Study of the Efficacy, Safety and Tolerability of Repeated Intravitreal Administration of VEGF Trap-Eye in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO) Completed NCT01012973 Phase 3
28 Trial to Reduce Alloimmunization to Platelets (TRAP) Completed NCT00000589 Phase 3
29 Indwelling Pleural Catheter for Trapped Lung: a Pilot Study for Power Calculation of a Randomized Controlled Trial Comparing Pleurocath® Versus PleurX®) Completed NCT03550027 Phase 3
30 A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF) Completed NCT02334748 Phase 3 canakinumab
31 A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs Completed NCT02059291 Phase 3 Canakinumab;Placebo
32 An Extension Study of CACZ885N2301 (NCT02059291), Multi-center, Open Label Study of Canakinumab in Japanese Patients With Periodic Fever Syndromes (Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyper Immunoglobulin D Syndrome ((Also Known as Mevalonate Kinase Deficiency) (HIDS/MKD), or Colchicine Resistant/Intolerant Familial Mediterranean Fever (crFMF)) Completed NCT02911857 Phase 3
33 A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer Unknown status NCT01652196 Phase 2 oxaliplatin;leucovorin;fluorouracil
34 A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients With Neovascular Age-Related Macular Degeneration Completed NCT00320788 Phase 2
35 A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1 Completed NCT01739036 Phase 1, Phase 2
36 Efficacy Study of ChAd63MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection. Completed NCT01666925 Phase 2
37 A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-Boost Malaria Vaccine Candidates: ChAd63 and MVA Encoding ME-TRAP and the Same Viral Vectors Encoding CS Completed NCT01623557 Phase 1, Phase 2
38 A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children Completed NCT01635647 Phase 1, Phase 2
39 Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With AdCh63 ME-TRAP and MVA ME-TRAP Completed NCT00890760 Phase 1, Phase 2
40 Efficacy Study of ChAd63-MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection Completed NCT01658696 Phase 2
41 A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP Completed NCT01142765 Phase 1, Phase 2
42 A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA Encoding ME-TRAP and Also RTS,S/AS01B Alone. Completed NCT01883609 Phase 1, Phase 2
43 An Open-label, Multicenter, Efficacy and Safety Study of 4-month Canakinumab Treatment With 6-month Follow-up in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS). Completed NCT01242813 Phase 2 ACZ885
44 A Phase I/IIa Sporozoite Challenge Study to Assess the Safety, Immunogenicity and Protective Efficacy of Intravenous Boosting With Malaria Vaccine Candidates ChAd63 and MVA Encoding ME-TRAP Completed NCT03707353 Phase 1, Phase 2
45 Phase I/II and Pharmacokinetic Study of Docetaxel Plus VEGF Trap (AVE0005, NSC# 724770) in Patients With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Completed NCT00436501 Phase 1, Phase 2 docetaxel
46 OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study. Completed NCT01802684 Phase 2
47 Randomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker Trial Completed NCT01538719 Phase 1, Phase 2 Rilonacept
48 X-TRAP: Phase I/II Study of Capecitabine Plus Aflibercept in Metastatic Colorectal Cancer Completed NCT01661972 Phase 1, Phase 2 Capecitabine and aflibercept
49 A Randomized, Single-Masked , Long-Term, Safety and Tolerability Study of Intravitreal VEGF Trap-Eye in Subjects With Neovascular Age-related Macular Degeneration Completed NCT00527423 Phase 2 VEGF Trap Eye
50 A Double-Masked, Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap-Eye in Patients With Diabetic Macular Edema (DME) Completed NCT00789477 Phase 2 Intravitreal Aflibercept Injection

Search NIH Clinical Center for Triiodothyronine Receptor Auxiliary Protein

Genetic Tests for Triiodothyronine Receptor Auxiliary Protein

Anatomical Context for Triiodothyronine Receptor Auxiliary Protein

MalaCards organs/tissues related to Triiodothyronine Receptor Auxiliary Protein:

40
Bone, Neutrophil, Endothelial, Lung, Liver, Bone Marrow, Eye

Publications for Triiodothyronine Receptor Auxiliary Protein

Articles related to Triiodothyronine Receptor Auxiliary Protein:

(show top 50) (show all 30001)
# Title Authors PMID Year
1
3,5,3'-triiodothyronine receptor auxiliary protein (TRAP) enhances receptor binding by interactions within the thyroid hormone response element. 57 61
1708100 1991
2
Accurate Modeling Methodology of Laterally Diffused Metal-Oxide Semiconductor Leakage Current for Electro-Static Discharge Protection Circuit Design. 61
33714308 2021
3
Characterization of Spatial Distribution of Trap Across the Substrate in Metal-Insulator-Semiconductor Structure with Band Bending Effect. 61
33714320 2021
4
Interface Trap Charge Effects of Monolithic 3D Junctionless Field-Effect Transistors (JLFET) Inverter. 61
33714311 2021
5
Characterization of edaphic fauna in different monocultures in Savanna of Piauí. 61
32876170 2021
6
SUMO pathway, blood coagulation and oxidative stress in SARS-CoV-2 infection. 61
33558851 2021
7
The study of gp130/the inflammatory factors regulating osteoclast differentiation in rheumatoid arthritis. 61
33604457 2021
8
Differential inflammatory and toxic effects in-vitro of wood smoke and traffic-related particulate matter from Sydney, Australia. 61
33482518 2021
9
Rickettsial agents detected in the genus Psathyromyia (Diptera:Phlebotominae) from a Biosphere Reserve of Veracruz, Mexico. 61
33486127 2021
10
Osteosarcoma-derived exosomal miR-501-3p promotes osteoclastogenesis and aggravates bone loss. 61
33529755 2021
11
Nanographene oxide modified phenyl methanethiol nanomagnetic composite for rapid separation of aluminum in wastewaters, foods, and vegetable samples by microwave dispersive magnetic micro solid-phase extraction. 61
33482488 2021
12
Expeditious COVID-19 similarity measure tool based on consolidated SCA algorithm with mutation and opposition operators. 61
33642960 2021
13
Distribution of mercury isotope signatures in Yundang Lagoon, Xiamen, China, after long-term interventions. 61
33601205 2021
14
Habitat-forming species trap microplastics into coastal sediment sinks. 61
33770872 2021
15
Ortho-silicic Acid Inhibits RANKL-Induced Osteoclastogenesis and Reverses Ovariectomy-Induced Bone Loss In Vivo. 61
32676940 2021
16
Role of vasodilator-stimulated phosphoprotein in RANKL-differentiated murine macrophage RAW264.7 cells: Modulation of NF-κB, c-Fos and NFATc1 transcription factors. 61
33747153 2021
17
Deficient endoplasmic reticulum translocon-associated protein complex limits the biosynthesis of proinsulin and insulin. 61
33811688 2021
18
Impact of the COVID-19 lockdown on roadside traffic-related air pollution in Shanghai, China. 61
33633432 2021
19
Influence of plant habitats on denitrification in lowland agricultural streams. 61
33636626 2021
20
Utilization of pit lake on the cleaning process of residual saltwater in unconfined coastal aquifers. 61
33508672 2021
21
An eco-parametric method to derive sedimentation rates for coastal saltmarshes. 61
33513503 2021
22
A potential Mg-enriched biochar fertilizer: Excellent slow-release performance and release mechanism of nutrients. 61
33444860 2021
23
Defect suppression and photoresponsivity enhancement in methylammonium lead halide perovskites by CdSe/ZnS quantum dots. 61
33524717 2021
24
Towards a model of wet deposition of bioaerosols: The raindrop size role. 61
33550056 2021
25
Influence of sequence length and charged residues on Swc5 binding with histone H2A-H2B. 61
33320380 2021
26
Magnetic particles as new adsorbents for the reduction of phosphate inputs from a wastewater treatment plant to a Mediterranean Ramsar wetland (Southern Spain). 61
33757273 2021
27
Commuter PM exposure and estimated life-expectancy loss across multiple transportation modes in Xi'an, China. 61
33690005 2021
28
Anti-osteoporotic effects of alisol C 23-acetate via osteoclastogenesis inhibition. 61
33524783 2021
29
Soil lead (Pb) and urban grown lettuce: Sources, processes, and implications for gardener best management practices. 61
33667819 2021
30
Investigation of Black Carbon characteristics over southern ocean: Contribution of fossil fuel and biomass burning. 61
33592443 2021
31
Structural changes induced by direct current magnetic field improve water holding capacity of pork myofibrillar protein gels. 61
33601660 2021
32
Ecological traps and boosters of ixodid ticks: The differing ecological roles of two sympatric introduced mammals. 61
33631488 2021
33
Improved selectivity for the determination of trinitrotoluene through reactive stage tandem ion mobility spectrometry and a quantitative measure of source-based suppression of ionization. 61
33676637 2021
34
Solar tick trap with a pheromone lure - A stand-in approach for off-host control of Rhipicephalus sanguineus sensu lato ticks. 61
33529987 2021
35
A comprehensive profiling and identification of liquiritin metabolites in rats using ultra-high-performance liquid chromatography coupled with linear ion trap-orbitrap mass spectrometer. 61
33222601 2021
36
How to avert a hidden trap: the severe obturator nerve re-flex. 61
33621008 2021
37
Evaluation of Mosquito Magnet and other collection tools for Anopheles mosquito vectors of simian malaria. 61
33794965 2021
38
Enhanced endothelial barrier function by monoclonal antibody activation of vascular endothelial cadherin. 61
33577432 2021
39
Immunoexpression pattern of autophagy mediators in alveolar bone osteoclasts following estrogen withdrawal in female rats. 61
33409945 2021
40
Acute ischemic stroke induces magnetic resonance susceptibility signs dominated by endothelial nitric oxide synthase activation. 61
33128486 2021
41
Multiple stressors and social-ecological traps in Pampean streams (Argentina): A conceptual model. 61
33097269 2021
42
Traffic-related air pollution is associated with glucose dysregulation, blood pressure, and oxidative stress in children. 61
33587949 2021
43
Residential proximity to major roadways and cognitive function among Chinese adults 65 years and older. 61
33097247 2021
44
Mineral trioxide aggregate (MTA) inhibits osteoclastogenesis and osteoclast activation through calcium and aluminum activities. 61
32789653 2021
45
RANK promotes colorectal cancer migration and invasion by activating the Ca2+-calcineurin/NFATC1-ACP5 axis. 61
33795653 2021
46
Notch signaling inhibition protects against root resorption in experimental immature tooth movement in rats. 61
33568273 2021
47
Biochemically identified neuropeptides in a caddisfly (Trichoptera) and a pygmy mole cricket (Orthoptera: Caelifera: Tridactyloidea). 61
33719129 2021
48
Superoxide-anion triggers impairments of immune efficiency and stress response behaviors of Eisenia fetida earthworms. 61
33189402 2021
49
Periodontal inflammation triggers a site-specific and wide radius of calcium metabolic effects on alveolar bone. 61
33314132 2021
50
Sediment trapping - An attempt to monitor temporal variation of microplastic flux rates in aquatic systems. 61
33529889 2021

Variations for Triiodothyronine Receptor Auxiliary Protein

Expression for Triiodothyronine Receptor Auxiliary Protein

Search GEO for disease gene expression data for Triiodothyronine Receptor Auxiliary Protein.

Pathways for Triiodothyronine Receptor Auxiliary Protein

GO Terms for Triiodothyronine Receptor Auxiliary Protein

Sources for Triiodothyronine Receptor Auxiliary Protein

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....